Epilepsy

An ongoing phase 2a study of RAP-219 involves adult patients with drug-resistant epilepsy who have an implanted responsive neurostimulation (RNS) device, allowing for real-time monitoring of intracranial EEG data.

NeurologyLive® will provide in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 10, 2024.

The global Phase 3 trial aims to enroll ~150 patients with Dravet syndrome who have SCN1A variants, assessing zorevunersen's impact on seizure frequency, behavior, cognition, and safety over 60 weeks, with results expected by 2027.

Lekha Rao, MD, an epileptologist at UCLA Health, discussed the challenges in diagnosing D/EE-SWAS, the importance of early EEG, and the need for greater awareness around this rare and complex epileptic condition.

Babitha Haridas, MD, MBBS, a pediatric epileptologist at Johns Hopkins Medicine, discussed the complexities with managing status epilepticus in Lennox-Gastaut syndrome, focusing on the importance of identifying triggers early in their condition.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed over the course of November 2024, compiled all into one place by the NeurologyLive® team.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched expert-led video series that appeared on the website in 2024.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 3, 2024.

As part of NeurologyLive®'s Year in Review, we've compiled the most-listened episodes of our biweekly podcast, Mind Moments®.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched interview clips that appeared on the website in 2024.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in epilepsy and seizure disorders in 2024.

As part of NeurologyLive®'s Year in Review, we've compiled the top coverage stories from 2024 across a variety of different neurological conferences the team either attended or covered virtually.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2024.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 20, 2024.

The chief medical officer at Stoke Therapeutics sat down at AES 2024 to discuss the promising data behind STK-001, an investigational antisense oligonucleotide in development for Dravet syndrome.

A duo from the Child Neurology Foundation discussed multidisciplinary collaboration, innovations in epilepsy care, and the importance of holistic, family-centric approaches to improving patient outcomes at AES 2024. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The professor of neurology at NYU Grossman School of Medicine discussed how innovative startups are using proof-of-concept studies and devices like responsive neurostimulators to improve patient outcomes. [WATCH TIME: 6 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neurostimulation to treat epilepsy.

Epileptologists Siddharth Jain, MD, MBBS, and Cemal Karakas, MD, provided commentary on a poster presentation at AES 2024 focusing on factors influencing seizure freedom in children who’ve experienced neonatal and perinatal arterial strokes.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 13, 2024.

The director of epilepsy surgery at Allegheny Health Network talked about recent advances in brain signal analysis with stereoelectroencephalography and its potential for transforming care for decision-making disorders. [WATCH TIME: 4 minutes]

Hugo Xi, head of Medical Neurology at UCB, discussed the company’s groundbreaking research, innovations in epilepsy care, and the company’s commitment to advancing treatments for rare syndromes at the 2024 AES Annual Meeting.

The pediatric epileptologist at Johns Hopkins Medicine discussed common triggers and potential preventive measures of status epilepticus in LGS, as well as the importance of involving families and caregivers. [WATCH TIME: 4 minutes]

The director of epilepsy surgery at Allegheny Health Network discussed how clinicians can successfully pinpoint the source of epilepsy in the brain through innovative procedures like stereo electroencephalography.

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona provided context on the potential of regenerative therapies like stem cells to restore neural function in patients with epilepsy. [WATCH TIME: 3 minutes]

Most treatment-emergent adverse events were mild or moderate, with low rates of serious TEAEs leading to discontinuation (1.7% in DS and 2.2% in LGS patients).